ARGENT gene expression regulation technology is expected to add a valuable tool to Regenx’s NAV platform by providing control of gene expression and the potential for safety and efficacy in certain disease populations.
This license also expands the market applications for NAV Technology in therapeutic areas where there is a need for precise calibration of pharmacologic control of gene expression.
As per the terms of the agreement, Regenx will have exclusive rights, along with the right to sublicense, to ARIAD‘s regulated gene expression system in the development and commercialization of human therapeutics and vaccines based on in-vivo gene delivery mediated by viral vectors, including but not limited to Regenx’s proprietary NAV vectors.
The agreement allows ARIAD to get clinical and regulatory milestones and royalties on products developed and commercialized using the Argent technology, as well as a portion of sublicensing revenues.
Regenx president and CEO Kenneth Mills said the option to include regulated gene expression via the NAV platform considerably expands their ability to develop therapeutic applications that require an increased level of control and a stabilized delivery process to ensure continual protein expression.